Medpace Holdings, Inc.
MEDPNASDAQHealthcare● Active
$457.90
+$3.65(+0.80%)
Market Cap$13.1B
P/E Ratio—
52W High$628.916
52W Low$293.2
Medpace Holdings, Inc. (MEDP) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
MEDP · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 22, 2026EPS Actual
$4.28
Est. $3.74 · +14.4%
Revenue
$0.71B
Est. $0.70B · +1.3%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 22, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue🔥 11-Quarter EPS Beat Streak
MEDP reports quarterly as a NASDAQ-listed Medical - Diagnostics & Research company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.21
Rev. $0.66B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.21
Rev. Est.$0.66B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Jul 20, 2026 | $3.98 | — | — | — | $0.69B | — |
| ▲ Q2 FY2026 | Apr 22, 2026 | $3.74 | $4.28 | +14.4% | $0.71B | $0.70B | +1.3% |
| ▲ Q1 FY2026 | Feb 9, 2026 | $4.19 | $4.67 | +11.5% | $0.71B | $0.69B | +2.8% |
| ▲ Q4 FY2025 | Oct 22, 2025 | $3.53 | $3.86 | +9.3% | $0.66B | $0.64B | +3.0% |
| ▲ Q3 FY2025 | Jul 21, 2025 | $2.98 | $3.10 | +4.0% | $0.60B | $0.54B | +12.0% |
| ▲ Q2 FY2025 | Apr 21, 2025 | $3.06 | $3.67 | +19.9% | $0.56B | $0.53B | +6.1% |
| ▲ Q1 FY2025 | Feb 10, 2025 | $2.96 | $3.67 | +24.0% | $0.54B | $0.54B | -0.6% |
| ▲ Q4 FY2024 | Oct 21, 2024 | $2.78 | $3.01 | +8.3% | $0.53B | $0.53B | -0.3% |
Q3 FY2026
Jul 20, 2026
EPS Actual
—
EPS Est.
$3.98
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 22, 2026Beat
EPS Actual
$4.28
EPS Est.
$3.74
EPS Surpr.
+14.4%
Revenue
$0.71B
Q1 FY2026
Feb 9, 2026Beat
EPS Actual
$4.67
EPS Est.
$4.19
EPS Surpr.
+11.5%
Revenue
$0.71B
Q4 FY2025
Oct 22, 2025Beat
EPS Actual
$3.86
EPS Est.
$3.53
EPS Surpr.
+9.3%
Revenue
$0.66B
Q3 FY2025
Jul 21, 2025Beat
EPS Actual
$3.10
EPS Est.
$2.98
EPS Surpr.
+4.0%
Revenue
$0.60B
Q2 FY2025
Apr 21, 2025Beat
EPS Actual
$3.67
EPS Est.
$3.06
EPS Surpr.
+19.9%
Revenue
$0.56B
Q1 FY2025
Feb 10, 2025Beat
EPS Actual
$3.67
EPS Est.
$2.96
EPS Surpr.
+24.0%
Revenue
$0.54B
Q4 FY2024
Oct 21, 2024Beat
EPS Actual
$3.01
EPS Est.
$2.78
EPS Surpr.
+8.3%
Revenue
$0.53B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2029 | $5.82 | $5.97 | $6.16 | 1 |
| Q3 FY2029 | $5.74 | $5.88 | $6.06 | 1 |
| Q2 FY2029 | $5.47 | $5.61 | $5.79 | 1 |
| Q1 FY2029 | $5.35 | $5.48 | $5.65 | 1 |
| Q4 FY2028 | $5.74 | $5.89 | $6.07 | 2 |
| Q3 FY2028 | $5.41 | $5.55 | $5.72 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2029 | $0.9B | $0.9B | $1.0B | 5 |
| Q3 FY2029 | $0.9B | $0.9B | $1.0B | 4 |
| Q2 FY2029 | $0.9B | $0.9B | $0.9B | 4 |
| Q1 FY2029 | $0.9B | $0.9B | $0.9B | 5 |
| Q4 FY2028 | $0.9B | $0.9B | $0.9B | 2 |
| Q3 FY2028 | $0.8B | $0.8B | $0.9B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | Apr 22, 2026 | +14.4% | $514.90 | $508.46 | -1.25% |
| ▲ Q1 FY2026 | Feb 9, 2026 | +11.5% | $542.04 | $530.35 | -2.16% |
| ▲ Q4 FY2025 | Oct 22, 2025 | +9.3% | $545.64 | $546.74 | +0.20% |
| ▲ Q3 FY2025 | Jul 21, 2025 | +4.0% | $311.87 | $308.88 | -0.96% |
| ▲ Q2 FY2025 | Apr 21, 2025 | +19.9% | $296.28 | $288.99 | -2.46% |
| ▲ Q1 FY2025 | Feb 10, 2025 | +24.0% | $354.10 | $354.51 | +0.12% |
| ▲ Q4 FY2024 | Oct 21, 2024 | +8.3% | $356.40 | $352.92 | -0.98% |
| ▲ Q3 FY2024 | Jul 22, 2024 | +8.3% | $421.31 | $437.18 | +3.77% |
Q2 FY2026-1.25%
Report Date
Apr 22, 2026
EPS Beat/Miss
+14.4%
Price Before
$514.90
Price After
$508.46
Q1 FY2026-2.16%
Report Date
Feb 9, 2026
EPS Beat/Miss
+11.5%
Price Before
$542.04
Price After
$530.35
Q4 FY2025+0.20%
Report Date
Oct 22, 2025
EPS Beat/Miss
+9.3%
Price Before
$545.64
Price After
$546.74
Q3 FY2025-0.96%
Report Date
Jul 21, 2025
EPS Beat/Miss
+4.0%
Price Before
$311.87
Price After
$308.88
Q2 FY2025-2.46%
Report Date
Apr 21, 2025
EPS Beat/Miss
+19.9%
Price Before
$296.28
Price After
$288.99
Q1 FY2025+0.12%
Report Date
Feb 10, 2025
EPS Beat/Miss
+24.0%
Price Before
$354.10
Price After
$354.51
Q4 FY2024-0.98%
Report Date
Oct 21, 2024
EPS Beat/Miss
+8.3%
Price Before
$356.40
Price After
$352.92
Q3 FY2024+3.77%
Report Date
Jul 22, 2024
EPS Beat/Miss
+8.3%
Price Before
$421.31
Price After
$437.18
Avg Beat Reaction-0.47%
Beat Rate8 / 8 quarters
Largest Move+3.77% (Q3 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: MEDP ends December
Medpace Holdings, Inc. (MEDP) most recently reported earnings on April 22, 2026 for Q2 FY2026, posting EPS of $4.28 — beating the analyst consensus of $3.74 by +14.4%. MEDP has beaten EPS estimates for 11 consecutive quarters. The next MEDP earnings date is expected around September 1, 2026.
Each quarter, investors track MEDP earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. MEDP revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
MEDP's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
MEDP earnings · 5 questionsMedpace Holdings, Inc.'s next earnings report is expected around September 1, 2026. MEDP typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; MEDP historically reports after market close (AMC).
MEDP earnings datewhen is MEDP earningsMEDP next earnings datewhen does MEDP report earningsMEDP earnings calendar
▸ Source: FMP · Medpace Holdings, Inc. SEC filings · US GAAP · Medpace Holdings, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026